Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.03. | Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin | 178 | ACCESS Newswire | Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submissionCompany expects to commence bioavailability study in April 2025Aspire intends... ► Artikel lesen | |
13.03. | Aspire Biopharma treibt Patentanmeldungen für Arzneimittelverabreichungstechnologie voran | 5 | Investing.com Deutsch | ||
13.03. | Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform | 196 | ACCESS Newswire | HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug... ► Artikel lesen | |
11.03. | SCD Media, LLC: An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation | 158 | Newsfile | New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual... ► Artikel lesen | |
03.03. | Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement | 193 | ACCESS Newswire | New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout marketDesert Stream Inc., a well-established nutritional and supplement manufacturer of... ► Artikel lesen | |
25.02. | Aspire Biopharma advances to phase 1 clinical trial for aspirin product | 2 | Investing.com | ||
ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
25.02. | Aspire Biopharma startet Phase-1-Studie für Aspirin-Produkt | 3 | Investing.com Deutsch | ||
25.02. | Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin | 343 | ACCESS Newswire | Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is completeTest results support the next development step with Phase 1clinical trial expected... ► Artikel lesen | |
21.02. | Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement | 490 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology... ► Artikel lesen | |
20.02. | Aspire Biopharma Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
20.02. | Aspire Biopharma announces public listing on Nasdaq | 2 | Seeking Alpha | ||
19.02. | Aspire Biopharma begins trading on Nasdaq post-merger | 3 | Investing.com | ||
19.02. | Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq | 397 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology... ► Artikel lesen | |
08.01. | Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
23.12.24 | Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
10.12.24 | Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
15.11.24 | Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
24.10.24 | Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations | 3 | SEC Filings | ||
03.09.24 | Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements | 196 | GlobeNewswire (Europe) | Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing... ► Artikel lesen | |
31.07.24 | Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp. | 94 | GlobeNewswire (Europe) | Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 63,13 | -0,19 % | Aktie bricht ein: 50 Prozent Minus in einem Jahr! Novo Nordisks CagriSema überzeugt nicht! | © Foto: Christian Schultz/dpaNovo Nordisk verliert die Hälfte seines Börsenwerts, nachdem schlechte Ergebnisse des Adipositas-Medikaments CagriSema die Hoffnungen der Anleger zerstörte.Novo Nordisk... ► Artikel lesen | |
GSK | 17,910 | +0,45 % | DEUTSCHE BANK RESEARCH stuft GSK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK auf "Hold" mit einem Kursziel von 1450 Pence belassen. Laut eigener Umfragen unter HIV-Ärzten und -Patienten zu den HIV-Präparaten... ► Artikel lesen | |
ROCHE | 310,70 | -0,10 % | Roche Aktie: Das läuft nicht rund | Die Roche-Aktie verzeichnete am Freitag deutliche Kursverluste an der Schweizer Börse. Im SIX SX-Handel gab das Papier im Tagesverlauf kontinuierlich nach und fiel bis zum Nachmittag um 1,2 Prozent... ► Artikel lesen | |
ELI LILLY | 760,80 | +0,16 % | Rückschlag für Novo-Rivale Eli Lilly | Das schmerzt: Die EU-Arzneimittelbehörde EMA hat dem US-Pharmariesen Eli Lilly kein grünes Licht für die Zulassung des Alzheimer-Medikaments erteilt. Der Wirkstoff Donanemab soll Patienten im Frühstadium... ► Artikel lesen | |
TEVA | 13,850 | -0,72 % | Teva Pharmaceutical Industries Ltd: Teva Releases Q1 2025 Aide Memoire | TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the "Investors" page on its... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 450,05 | -0,57 % | Vertex to take $400M impairment charge as it abandons diabetes drug program | ||
QUANTUM BIOPHARMA | 7,500 | -6,83 % | Quantum BioPharma Ltd.: Quantum BioPharma Provides Corporate Update | Toronto, Ontario--(Newsfile Corp. - March 30, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to... ► Artikel lesen | |
CSPC PHARMA | 0,577 | -0,52 % | CSPC Pharmaceutical Group-Aktie leicht im Plus (0,5752 €) | Im Plus liegt derzeit die Aktie der CSPC Pharmaceutical Group . Die Aktie notiert aktuell bei 0,58 Euro. Der Anteilsschein der CSPC Pharmaceutical Group verzeichnet zur Stunde einen Preisanstieg von... ► Artikel lesen | |
ROCKET LAB USA | 17,250 | +0,58 % | Rocket Lab USA, Inc.: Rocket Lab Successfully Launches Mission for Global Wildfire Detection Company OroraTech | From contract to launch in just four months, Rocket Lab successfully deploys eight satellites for wildfire detection mission.
Rocket Lab USA, Inc. (Nasdaq: RKLB) ("Rocket Lab" or "the Company")... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 19,950 | -25,20 % | New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. | Sponsored by The Sustainable Green Team (OTC: SGTM), featuring Kevin Harrington - the ORIGINAL Shark from Shark Tank NEW YORK CITY, NEW YORK / ACCESS Newswire / March 29, 2025 / New to The Street, the... ► Artikel lesen | |
PENTIXAPHARM | 3,250 | -4,41 % | EQS-AFR: Pentixapharm Holding AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Pentixapharm Holding AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Pentixapharm Holding AG: Vorabbekanntmachung... ► Artikel lesen | |
APONTIS PHARMA | 11,600 | +1,31 % | Original-Research: APONTIS PHARMA AG (von Montega AG): End of Coverage | Original-Research: APONTIS PHARMA AG - von Montega AG 07.03.2025 / 13:07 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
XORTX THERAPEUTICS | 0,918 | +1,32 % | XORTX gibt Update zu Gesprächen mit der FDA bekannt | - Gespräche im Rahmen eines Typ-B-Meetings für ein verkürztes NDA-Zulassungsverfahren für XRx-026 zur Gichtbehandlung
CALGARY, ALBERTA, den 19. März 2025 / IRW-Press / XORTX... ► Artikel lesen | |
CATALYST PHARMACEUTICALS | 22,430 | -1,49 % | Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win | ||
TG THERAPEUTICS | 36,275 | -1,49 % | MaxCyte, Inc: MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs | ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery... ► Artikel lesen |